Taken together, clinical evidence suggests that the ATX–LPA axis is positively associated with impaired glucose homeostasis and insulin resistance, and that ATX-LPA may serve as a therapeutic target and/or marker for obesity-related insulin resistance in humans. The gene discussed is LPA; the disease is obesity disorder.